uniQure Grants Chiesi Select Commercial Rights For The EU’s First Approved Gene Therapy Glybera And Hemo B Gene Therapy
This article was originally published in The Pink Sheet Daily
uniQure has licensed commercial rights covering Europe and select emerging markets to Italy’s Chiesi for first-to-market gene therapy Glybera and a developmental hemophilia B product. The Dutch biopharma is writing the book on pricing and commercialization, regulatory approval, and market access strategy for gene therapy.
You may also be interested in...
Insider participation continues to play an important role in getting a majority of biotech IPOs off the ground; and it’s not clear if or when that trend will change. Plus, news on recent financings by Dicerna, uniQure, Lumos Pharma and NightstaRx.
New therapeutic modalities can bring unexpected challenges in pricing, as uniQure and electroCore learn. Also, deal news from Celgene/OncoMed, Forest/Merck, Theraclone/PharmAthene, The Medicines Company/Rempex and Roche/Molecular Partners.
The purchase of Zymenex by Italy’s Chiesi has allowed VC firm Sunstone Capital to reap a second return on its investment in the Danish developer of enzyme replacement therapies.